Financial Shenanigans

The Forensic Verdict

Ginkgo earns an Elevated forensic risk grade (score 52/100). The reported losses look directionally honest — cash burn each year is larger than the GAAP loss net of stock comp and impairments — but the file of accounting-adjacent events is unusually heavy: a $17.75M securities class action settlement (final approval December 2024) over allegations of undisclosed related-party revenue, a remediated material weakness in ICFR for fiscal 2023, a CFO transition completed mid-2025, a full write-off of Cell Engineering goodwill in Q2 2024, and a quiet retirement of the three "Programs" KPIs management had highlighted for years. Offsetting: the audit committee's own forensic investigation (Milbank/Ankura) concluded no restatement was required, no current 10-K carries a going-concern emphasis, and FY2025 cash burn is shrinking. The single data point that would most change the grade is a clean Q1 2026 10-Q with no new material weakness, restatement, or non-cash revenue release — that would justify a downgrade toward "Watch."

Shenanigans Scorecard

The thirteen categories of the standard playbook, ranked by what actually moves the underwriting thesis for Ginkgo.

Breeding Ground

The corporate environment is the most concerning part of the file: a founder-controlled, dual-class company that already drew a securities settlement, a derivative settlement, and a material-weakness disclosure within the last twenty-four months. Independent oversight exists on paper (five of seven directors are independent) but voting power is concentrated and the co-founders include a married couple.

The breeding ground amplifies the accounting concerns rather than dampening them. The dual-class structure means founders can override an independent audit committee in extremis, the litigation file is already non-trivial, and a remediated material weakness shows management can spot problems but does not eliminate the risk of new ones. The clean offsets — auditor stability and no admitted misconduct — keep this from being a "Critical" file, but the structural conditions for shenanigans are present.

Earnings Quality

Reported losses understate underlying cash burn over the cycle, but the quality of the revenue line itself has deteriorated: a meaningful portion of recent revenue comes from one-time releases of deferred balances on terminated contracts rather than performance of new work.

Revenue is collapsing — and a chunk is non-cash, non-recurring

Cell Engineering revenue in FY2024 included a $45.4M release of deferred revenue tied to the terminated Motif FoodWorks contract plus a $4.5M release tied to a terminated related-party contract — together about 22% of total FY24 revenue, and revenue for which Ginkgo was no longer obligated to perform work. FY2025 includes another $7.5M from the terminated BiomEdit contract. These are accounting-correct releases under ASC 606 (deferred balance must come off the balance sheet when performance obligation is extinguished), but they materially inflate the apparent recurring revenue base and the year-over-year comparison.

Equity-payment revenue ("non-cash consideration" for licenses) fell from $61.4M in FY24 to $11.6M in FY25 — a steep decline, partly driven by the Motif release no longer recurring. Backing out both items leaves underlying cash-customer revenue closer to $158M in FY25 versus $166M in FY24 — much flatter than the headline implies.

Non-cash charges absorb most of the GAAP loss

Net income is consistently larger (more negative) than CFO because of stock-based compensation, impairments, deconsolidation losses, and IPR&D charges. Notable peaks: FY2021 SBC of $1.61B and FY2022 SBC of $1.93B reflect the catch-up vesting from the September 2021 SPAC merger with Soaring Eagle. SBC normalized to $230M in FY23 and continues to decline.

Stock-based compensation and impairments dominate the gap

FY24 saw the full $47.9M goodwill write-off of the Cell Engineering reporting unit plus $5.8M of lab equipment impairment plus $19.8M of acquired in-process R&D expensed. These charges align with the Q2 2024 restructuring announcement and a sustained drop in market capitalization — appropriate impairment timing, but the cluster of one-time charges immediately preceding the CFO change is the pattern most worth tagging in case future periods bring more.

Receivables are small but moving the wrong way

Days sales outstanding has crept from 26 days at the end of FY23 to 52 days at the end of FY25. Revenue fell 25% year-over-year in FY25, while receivables grew about 8% — a 33 percentage point gap. The absolute receivables base is tiny ($24M), so this is not, on its own, an aggressive-revenue signal — but for a shrinking revenue line, rising DSO bears watching in the next two quarters, especially given the historical class-action allegations about related-party billing.

Cash Flow Quality

Operating cash flow has improved sharply in FY2025 — but most of the improvement is the disappearance of restructuring cash outflows, not an underlying business turn.

Free cash flow improved from negative $382M in FY24 to negative $179M in FY25 — a $203M swing. But:

• $56M comes from capex collapsing from $62.5M to $7.7M. Property, plant and equipment fell from $598M to $528M and depreciation was $59M, so the company is consuming its installed asset base without renewing it. Capex/Depreciation of 0.13 is the lowest in the disclosed history. This is a deliberate restructuring choice (Ginkgo says the FY24 spend was for a new lab build-out near headquarters), but it is not a permanent run rate.

• $148M of the CFO improvement is mainly the working-capital normalization after FY24's restructuring cash outflows (which included $40M of decreases in accrued expenses and restructuring/litigation payments). The FY25 cash-flow note discloses that net change in operating assets and liabilities was negative $44M, with the largest line being a $32M reduction in deferred revenue tied to those non-cash terminated contracts — which means the deferred-revenue release added to GAAP revenue but subtracted from CFO, partly offsetting the optical improvement.

• Working-capital structure is benign at present. Accounts payable is $11M, receivables are $24M, and the company does not disclose factoring, supplier finance, securitization, or recourse arrangements. There is no inflated CFO via "shifting financing inflows" — the worry is the opposite, that the FY25 reading flatters the underlying burn.

The acquisition-adjusted FCF question is moot for Ginkgo because acquisition outflows have been small ($5.4M in FY24, zero in FY25). The historical FY22 cash-flow statement shows an "Acquisitions" line of positive $74.7M — that is the deconsolidation effect of Zymergen entering bankruptcy in 2023 and being removed from Ginkgo's consolidated cash account, not a recurring source of cash.

Metric Hygiene

Management's preferred metric is Adjusted EBITDA. The reconciliation excludes a long list of items that, while non-cash in form, have nonetheless been recurring in nature across the last three years.

The Adjusted EBITDA reconciliation strips out roughly $145M of items in FY25 alone. Most of these are defensible (SBC, restructuring, change in fair value of warrants, deconsolidation losses). The two adjustments worth scrutiny are:

The headline KPI changes are also material. The "Programs" framework — New Programs added, Current Active Programs, Cumulative Programs since inception — was the company's preferred operating metric throughout the FY2019 to FY2024 disclosures and grew every year: from 16 New Programs in FY19 to 78 in FY23. Management stopped publishing those metrics from Q4 2024, citing the restructuring and "new service offerings." The replacement metric has not been announced. Stopping a previously highlighted growth metric without replacement is the most textbook key-metric shenanigan in the playbook.

What to Underwrite Next

The top items to track over the next two quarters are concrete and named.

1. Q1 2026 10-Q for discontinued-operations recast. The Biosecurity divestiture closed April 3, 2026 and Q1 2026 will be the first period to show Biosecurity as held-for-sale / discontinued operations. Watch (a) the recast historical revenue base, (b) any gain or loss on the sale, and (c) the residual cash retained, working capital retained, and indemnification provisions. The recast will materially change the apparent revenue growth profile.

2. Receivables and DSO trajectory. Receivables grew 8% in FY25 against a 25% revenue decline. DSO has climbed three years in a row from 26 to 52 days. Next stop to monitor is 65 days — at that level, on a shrinking revenue base, the pattern becomes worth a question.

3. Deferred revenue balance and the next contract termination. Each terminated customer contract triggers a deferred-revenue release. Watch the deferred revenue note for the FY26 balance and any new related-party or affiliated-program terminations. A second large release in FY26 would convert this from a yellow flag to a red flag.

4. Capex normalization. FY25 capex of $7.7M is unsustainable against $59M of depreciation. The board would normally fund $30–60M of maintenance capex on this asset base. Either the FY26 number rises sharply (a deferred-spending unwind) or asset productivity declines materially. Either way, the FY25 free-cash-flow optics are temporary.

5. CFO continuity and audit-committee posture. Steven Coen has been in seat under a year. Watch for (a) re-disclosure of a new KPI framework, (b) any new material weakness, (c) a change in critical accounting estimates language, and (d) any new related-party disclosure under Item 13.

Downgrade triggers (toward "Watch"): Clean Q1 2026 and Q2 2026 10-Qs with no new material weakness, no new contract termination requiring deferred-revenue release, a new KPI framework that reconciles to revenue, DSO stable or improving, and the Biosecurity sale producing the announced consideration.

Upgrade triggers (toward "High"): A new material weakness, an SEC inquiry, an auditor change, a related-party disclosure not previously in the public record, a new revenue restatement, or revenue contraction that is hidden behind further deferred-revenue releases.

The forensic file matters for valuation. Three observations should flow into the underwriting model: (a) discount the Adjusted EBITDA line by at least the SBC add-back ($82M) and the deferred-revenue release ($7.5M); (b) treat FY25 FCF as flattered by capex deferral by roughly $30–40M; (c) do not give credit for the historical "Programs" growth narrative until a comparable metric is re-disclosed. Combined, this is a position-sizing limiter rather than a thesis breaker — but only because the auditor and audit committee have so far stayed clean. If that changes, this report should change too.